Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Anti-viral Efficacy of Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

NCT05047783 is registered in ClinicalTrials.gov with AB Science as lead sponsor.

NCT NCT05047783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05047783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Anti-viral Efficacy of Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
Lead sponsor
AB Science
Phase
Phase 2
Overall status
Unknown status
Start date
November 23, 2021
Completion date
December 31, 2023
Enrollment
78 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease 2019, covid19, sars-cov2 infection